Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.
{iframe}http://www.catalent.com/index.php/news-events/news/Catalent-to-acquire-gene-therapy-leader-Paragon-Bioservices-Inc.-for-1.2-billion{/iframe}